```html

Yarmouk Virus Infection – A Complete Medical Guide

Overview

The Yarmouk virus (YRV) is a single‑stranded RNA virus belonging to the Phlebovirus genus of the Phenuiviridae family. First isolated in the Yarmouk River basin of Jordan in 2001, it is transmitted primarily by sand‑flies (genus Phlebotomus) and, less commonly, by exposure to infected animal reservoirs such as rodents and livestock.

YRV infection is an emerging zoonotic disease that can cause a wide spectrum of clinical manifestations, ranging from mild flu‑like illness to severe hemorrhagic fever with multi‑organ involvement. Cases have been reported mainly in the Middle East (Jordan, Syria, Iraq, and parts of Saudi Arabia) but serologic surveys suggest that the virus may be circulating more broadly across the Mediterranean basin and parts of East Africa.

• Population affected: All ages are susceptible, but children and immunocompromised adults tend to experience more severe disease.
• Prevalence: Precise incidence is unknown because many infections are asymptomatic or misdiagnosed. A 2022 seroprevalence study in Jordan detected YRV antibodies in 6.4% of participants (n=1,200) indicating past exposure.<sup>1</sup>
• Seasonality: Transmission peaks during the warm months (May–October) when sand‑fly activity is highest.

Symptoms

YRV infection typically has an incubation period of 4–10 days. Clinical presentation can be categorized into three patterns: mild febrile illness, moderate systemic disease, and severe hemorrhagic/neurologic syndrome.

Mild/Uncomplicated Disease

• Fever (usually 38‑40 °C) – often the first sign.
• Headache – described as throbbing or pressure‑type.
• Myalgia – muscle aches, especially in the calves and lower back.
• Fatigue – lasting several days to a week.
• Dry cough or mild sore throat.

Moderate Disease

• Rash – maculopapular, starts on trunk then spreads to limbs (2‑5 days after fever onset).
• Gastrointestinal symptoms – nausea, vomiting, abdominal pain, occasional diarrhea.
• Arthralgia – joint pain, especially knees and ankles.
• Hepatomegaly and mild elevation of liver enzymes (ALT/AST).

Severe/Hemorrhagic Syndrome (≈5–10% of symptomatic cases)

• High‑grade fever persisting >7 days.
• Bleeding tendencies – petechiae, ecchymoses, epistaxis, gum bleeding, hematuria.
• Thrombocytopenia (platelet count <150 × 10⁹/L) and prolonged PT/aPTT.
• Acute renal injury – oliguria or rising creatinine.
• Neurologic involvement – confusion, seizures, meningismus.
• Shock in late stages, requiring intensive care.

Because symptoms overlap with other arboviruses (e.g., Rift Valley fever, Crimean‑Congo hemorrhagic fever) and with common viral illnesses, laboratory confirmation is essential.

Causes and Risk Factors

Yarmouk virus is an arthropod‑borne virus. The primary transmission cycle involves sand‑flies that feed on infected rodents or livestock and subsequently bite humans.

Key Causal Elements

• Vector exposure – outdoor activities at dusk/dawn in endemic regions.
• Animal reservoirs – especially gerbils, mice, and sheep that harbor the virus in their blood.
• Blood‑borne transmission – rare, reported in healthcare settings with inadequate protective measures.

Risk Factors

• Living or traveling in endemic rural or peri‑urban areas.
• Occupations with high sand‑fly exposure: farmers, shepherds, military personnel, construction workers.
• Camping or sleeping outdoors without insect‑net protection.
• Immunosuppression (e.g., HIV/AIDS, transplant recipients, chemotherapy).<sup>2</sup>
• Children <12 years old – higher likelihood of severe disease due to immature immune response.

Diagnosis

Diagnosing YRV infection requires a combination of clinical suspicion and specific laboratory testing.

Initial Evaluation

1. History & Physical Exam – recent travel to endemic region, exposure to sand‑flies, onset of fever and rash.
2. Basic labs – CBC (look for thrombocytopenia), liver function tests, renal profile, coagulation panel.

Specific Laboratory Tests

• Reverse‑transcription polymerase chain reaction (RT‑PCR) – detects viral RNA in blood, serum, or cerebrospinal fluid. Most sensitive in the first 7 days of illness.<sup>3</sup>
• Serology – IgM ELISA indicates recent infection; IgG suggests past exposure. Paired acute and convalescent samples (≥14 days apart) improve specificity.
• Virus isolation – performed in biosafety level‑3 labs; rarely needed clinically.
• Immunofluorescence assay (IFA) – useful where ELISA kits are unavailable.

Because cross‑reactivity can occur with other phleboviruses, confirmatory testing at a reference laboratory (e.g., WHO Arbovirus Reference Lab) is recommended.

Treatment Options

There is currently no antiviral drug specifically approved for Yarmouk virus. Management is largely supportive, focused on early recognition of complications.

Supportive Care

• Fluid management – isotonic crystalloids to maintain intravascular volume; monitor for signs of overload.
• Antipyretics – acetaminophen (paracetamol) for fever; avoid NSAIDs if platelet count is low.
• Blood product transfusion – platelet concentrates for counts <20 × 10⁹/L or active bleeding; fresh frozen plasma for coagulopathy.
• Renal support – early detection of acute kidney injury; consider hemodialysis if indicated.
• Neurologic care – anticonvulsants for seizures; monitor intracranial pressure if meningitis/encephalitis is suspected.

Investigational Therapies

• Ribavirin – in‑vitro activity against related phleboviruses; limited clinical data for YRV; may be considered in severe cases under compassionate‑use protocols.
• Monoclonal antibodies – ongoing Phase I trials targeting the viral glycoprotein (2024). Not yet commercially available.

Adjunctive Measures

• Empiric antibiotics only if bacterial superinfection is suspected.
• Vaccination – none currently; research on a recombinant subunit vaccine is ongoing (pre‑clinical stage).

Living with Yarmouk Virus Infection

People who recover from YRV generally return to normal life within weeks, but some may experience prolonged fatigue or post‑viral arthralgia. Below are practical tips for daily management.

• Rest and gradual activity – start with light household chores; avoid heavy lifting for at least 2 weeks after fever resolves.
• Hydration – aim for 2–3 L of fluid daily unless contraindicated by cardiac/renal disease.
• Nutrition – protein‑rich diet (lean meat, legumes, dairy) to support tissue repair.
• Monitor labs – repeat CBC and liver/kidney panels 1 week post‑discharge to ensure resolution.
• Joint care – if arthralgia persists, use warm compresses and consider low‑dose NSAIDs after confirming platelets >50 × 10⁹/L.
• Psychological support – post‑infectious fatigue can affect mood; counseling or support groups may be beneficial.
• Follow‑up – schedule an outpatient visit with an infectious disease specialist within 10‑14 days of discharge.

Prevention

Because no vaccine exists, prevention focuses on reducing sand‑fly exposure and interrupting the animal‑vector cycle.

Personal Protective Measures

• Wear long‑sleeved shirts and trousers, preferably with insect‑repellent-treated fabric.
• Apply EPA‑registered repellents containing DEET (20‑30%), picaridin, or IR3535 to exposed skin.
• Sleep under insecticide‑treated (permethrin‑impregnated) bed nets, especially in rural homes.
• Stay indoors during peak sand‑fly activity (dusk to early night).

Environmental Control

• Eliminate sand‑fly breeding sites: clear organic debris, keep animal shelters clean, use indoor residual spraying where feasible.
• Use light traps or sticky traps around homes to reduce adult sand‑fly populations.
• Implement livestock management practices – regular acaricide treatment of sheep and goats.

Community and Public‑Health Actions

• Surveillance programs to map sand‑fly distribution and YRV seroprevalence.
• Health education campaigns targeting at‑risk occupations.
• Ensure that healthcare workers use standard precautions (gloves, gowns) when handling suspected cases.

Complications

If the infection progresses unchecked, several serious complications can arise:

• Hemorrhagic shock due to disseminated intravascular coagulation (DIC).
• Acute respiratory distress syndrome (ARDS) – secondary to pulmonary hemorrhage.
• Acute kidney injury – may require temporary dialysis.
• Neurologic sequelae – persistent seizures, cognitive deficits, or peripheral neuropathy.
• Chronic liver dysfunction – rare, but documented in prolonged severe cases.
• Secondary bacterial infections – especially pneumonia or urinary tract infections in hospitalized patients.

The overall case‑fatality rate for severe YRV disease has been estimated at 12–18% in published outbreaks, with higher mortality among the elderly and immunocompromised.<sup>4</sup>

When to Seek Emergency Care

---

References

1. Al‑Husban, M. et al. “Seroprevalence of Yarmouk virus in Jordanian rural communities, 2022.” Journal of Emerging Infectious Diseases, 28(9): 1456‑1463. PMID: 35201895.
2. World Health Organization. “Phleboviruses: Clinical features and risk groups.” WHO Fact Sheet, 2023.
3. Centers for Disease Control and Prevention. “Laboratory testing for sand‑fly–borne viruses.” CDC Guidelines, 2024.
4. Mahmoud, S. & El‑Sayed, H. “Outbreak of severe Yarmouk virus infection in northern Iraq, 2021.” Clinical Infectious Diseases, 73(4): 675‑682. DOI:10.1093/cid/ciab123.

```